Maternal Serum Periostin as a Potential Biomarker for Gestational Diabetes Mellitus and Adverse Perinatal Outcomes.

EROĞLU S., Gumusburun N., Ürkmez S. S., Civil Ürkmez Y., Çelik S., Şahin K.

Zeitschrift fur Geburtshilfe und Neonatologie, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası:
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1055/a-2827-9333
  • Dergi Adı: Zeitschrift fur Geburtshilfe und Neonatologie
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: biomarker, Gestational diabetes mellitus, periostin, second trimester
  • Samsun Üniversitesi Adresli: Evet

Özet

Objective To investigate whether maternal serum periostin levels measured in the second trimester can serve as a biomarker for gestational diabetes mellitus (GDM) and predict perinatal outcomes. Methods This prospective case-control study included 173 pregnant women (103 with GDM and 70 healthy controls). Serum periostin levels were measured between 15-20 weeks of gestation. GDM was diagnosed using a 75-g oral glucose tolerance test at 24-28 weeks. Receiver operating characteristic (ROC) analysis and logistic regression were used to evaluate diagnostic performance. Results Serum periostin levels were significantly higher in the GDM group compared to controls (median: 50.7 vs. 33.7 ng/mL, p<0.001). Periostin showed moderate diagnostic accuracy for GDM (AUC: 0.752). Higher periostin levels were associated with cesarean delivery, neonatal intensive care unit admission, and meconium-stained amniotic fluid. Conclusion Elevated maternal serum periostin levels in the second trimester are associated with gestational diabetes msellitus and adverse perinatal outcomes. Periostin may serve as a supplementary biomarker for early identification of GDM.